Intimation of grant of 830050 options under Rossari Employee Stock Option Plan - 2019.

Rossari Biotech's Board of Directors met on May 27, 2026 and approved two key items. First, the re-appointment of Ms. Esha Padmanabhan Achan as a Non-Executive Independent Director for a second term of 3 years from October 21, 2026 to October 20, 2029, subject to shareholder approval. Ms. Esha is a finance professional with 33 years of experience, having held senior roles at Glenmark Pharmaceuticals and Bajaj. Second, the Board approved grant of 830,050 stock options under the Rossari Employee Stock Option Plan - 2019, convertible into an equal number of equity shares at an exercise price of Rs. 537 per option. The options vest over 4 years (20% each year for first 3 years, 40% in the 4th year) and must be exercised within 5 years of vesting.